Posts by Mike Mooney
Study Investigates if Clinical PSP Diagnoses Match Neuropathology in a National Dataset
A study published in the medical journal Alzheimer’s & Dementia finds disagreement between progressive supranuclear palsy (PSP) diagnoses made in-clinic and brain autopsies in the National Alzheimer’s Coordinating Center’s (NACC)…
Read MoreAmylyx Pharmaceuticals Ends PSP Trial of AMX0035
Amylyx Pharmaceuticals announced recently that it would end its phase 2b trial of its drug AMX0035 for the treatment of progressive supranuclear palsy (PSP). The trial will not proceed to…
Read MoreAFTD and ADDF Award $2.5 million to Vesper Biotechnology for Drug VES001 Clinical Trial in FTD
The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer’s Drug Discovery Foundation (ADDF) recently awarded $2.5 million as part of their shared funding opportunity called the Treat FTD Fund to Danish biotechnology…
Read MoreFTD Science Digest – Collaboration for Future FTD Clinical Trials: the 2025 FTD Research Roundtable
This September marked the third annual FTD Research Roundtable hosted by AFTD. This event brings together diverse stakeholders, particularly industry partners, working towards addressing barriers to finding disease-modifying therapies for…
Read MoreMeet the Researcher: Indira García-Cordero, PhD
“Over the years, I have had the privilege of meeting and working with people living with FTD and their families. Their strength and resilience have inspired me and motivated me…
Read MoreFTD Research Spotlight – Collaboration for Future FTD Clinical Trials: the 2025 FTD Research Roundtable
This September marked the third annual FTD Research Roundtable hosted by AFTD. This event brings together diverse stakeholders, particularly industry partners, working towards addressing barriers to finding disease-modifying therapies for…
Read More
